Figure 3 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer

Atish Dipankar Choudhury, Caiwei Zhong, Wanling Xie, Bose S. Kochupurakkal, Peter I-Fan Wu, Irbaz Bin Riaz, Ruolin Liu, David Dewei Yang, Edmund Folefac, Daniel Lee, Mamta Parikh, David Johnson Einstein, Elizabeth Riley Kessler, Tina M. Mayer, Rana R. McKay, Amanda Fredericks Pace, Kent William Mouw, Li Chen, Viktor A. Adalsteinsson, Eliezer M. Van Allen, Charles A. Kunos, Steven D. Gore, Biswajit Das, Alan D. D’Andrea, Mary‐Ellen Taplin, Geoffrey Ira Shapiro

Published Sep 18, 2026Paper ↗

65%

OverallWorth a look

OverallWorth a lookVote to see the score

Readers

–

Only vote on papers you've read. Sign in to vote.

AI panel3/20reviewers recommend it

lenient 1/5

medium 0/10

strict 2/5

AI panel?Vote to see what the 20 AI reviewers said

Abstract

HRD status does not demonstrate a statistically significant correlation with clinical benefit in either arm. Kaplan–Meier plots for PFS per PCWG3 criteria with patients across both arms and stratified by (A) HRD status determined by deleterious DDR gene mutations identified by WES of tumor biopsy, (B) RAD51 foci–based IHC, (C) DirectHRD analysis of WGS of cfDNA using a cutoff of 2.5 in the overall cohort, and (D) DirectHRD analysis of WGS of cfDNA using a cutoff of 2.5 in arm B only. NE, not estimable.